The success of Sildenafil initially sparked a surge for pharma, but recent shifts present a murky outlook for investors. Lower-cost versions are reducing revenue, and persistent legal battles add further risk to the https://laylamyzm506538.liberty-blog.com/41467237/viagra-and-pharma-a-volatile-investment